- At least one RAI-avid lesion identified on a radioiodine scan (a diagnostic, post-therapy, or post-ablation scan) performed <24 months prior to study registration. (Both RAI-sensitive and RAI-refractory patients are eligible if at least one tumor with RAI avidity of any degree can be identified within these parameters.)